Phase II Single-Arm Study to Assess Trastuzumab and Vinorelbine in Advanced Breast Cancer Patients With HER2-Negative Tumors and HER2-Positive Circulating Tumor Cells.
Heather A ParsonsErin R MacraeHao GuoTianyu LiWilliam T BarryNabihah TayobGerburg M WulfSteven Jay IsakoffIan E KropPublished in: JCO precision oncology (2022)
CTC analysis of patients with HER2-negative MBC identifies a subset with HER2-amplified CTCs. However, clinical activity of an HER2-directed regimen in this population was low. The functional significance of HER2-positive CTCs remains uncertain.